Paclitaxel plus Cirmtuzumab Achieves Greater Clearance of Patient-derived Xenografts By Targeting ROR1+ Breast Cancer Stem Cells
Ontology highlight
ABSTRACT: We applied high-throughput sequence to identify signaling pathways, stem cell gene signature or target genes of BMI1 that were affected by our newly development humainzed anti-ROR1 antibody (cirmtuzumab) in breast cancer patient-derived xenograft (PDX) mice model
ORGANISM(S): Homo sapiens
PROVIDER: GSE108632 | GEO | 2019/01/16
REPOSITORIES: GEO
ACCESS DATA